An improved procedure for the manufacture of 4-hydroxy-2-methyl- N -(5-methyl-1,3-thiazol-2-yl)-2 H -1,2-benzothiazine-3-carboxamide 1,1-dioxide (meloxicam) is described. The key intermediate of this protocol is the new potassium salt monohydrate of meloxicam, which makes possible the efficient removal of impurities, resulting in an environmentally friendly manufacturing process of the high-purity (>99.90%) drug substance.
No takes yet. Share an insight, caveat, or question.
Mezei et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: